ANNOUNCEMENT: Stephen Hermitage joins Sai Life Sciences as Vice President of CMC

(Information sent by the signatory company).

ANNOUNCEMENT: Stephen Hermitage joins Sai Life Sciences as Vice President of CMC

(Information sent by the signatory company)

MANCHESTER, England and HYDERABAD, India, Nov. 23, 2022 /PRNewswire/ -- Sai Life Sciences, a liaison, today announced the addition of Stephen Hermitage (Steve) as Vice President of CMC. In this role, Steve will join the global RD leadership team at Sai Life Sciences, where he will add further scientific, process development and drug development expertise to the RD organization.

Making the announcement, Sauri Gudlavalleti, COO, commented: "Over the past few years, our team has established a formidable reputation as a high-quality scientific unit that can solve complex chemical challenges. I am delighted to welcome Steve, a pharmaceutical industry veteran, aboard Sai Life Sciences His addition to our global delivery team further strengthens our ongoing efforts to build strong customer partnerships and exceed customer expectations by raising the bar on innovation, speed and efficiency".

Steve joins Sai Life Sciences from GlaxoSmithKline (GSK), where he was a department head and member of the global chemical development leadership team. During more than 24 years at GSK, Steve has successfully worked with many project leaders and their teams to deliver API and regulatory submissions that facilitate preclinical and clinical activities throughout the entire development lifecycle, from development to development. Accelerated pragmatic early-stage delivery to complex QBD strategies to archival support and commercial launch. Throughout his time with GSK, Steve gained significant experience working with CDMOs in India, China and Europe, having led the technical outsourcing group within Chemical Development.

Elaborating on Steve's role, Dean Edney, Global Head of Process R&D, explained: "Steve will bring best practice in liaison to programs in Manchester and Hyderabad. His experience will also provide new perspectives on project and program management. , ensuring that we continue to build towards excellence in partnership with the client."

Steve has a BA and MA from the University of Oxford, a PhD from the University of Liverpool and did post-doctoral studies at the University of Cambridge. He is a Fellow of the Royal Society of Chemistry and a Chartered Chemist (FRSC CChem).

Commenting on his appointment, Steve Hermitage said: "I am incredibly excited to join Sai Life Sciences at a transformational time for the company. Through all my interactions with colleagues in the company, it is clear that there is a collective ambition to build a world-leading organization that delivers projects for clients by combining sound science with efficient manufacturing capability while maintaining high standards in safety and quality."

About Sai Life Sciences

Sai Life Sciences is a full-service CRO-CDMO working with innovative pharmaceutical and biotech companies globally to accelerate the discovery, development and commercialization of complex small molecules. The company has more than 2,200 employees at its facilities in India, the United Kingdom and the United States. Sai Life Sciences is a private company and is backed by global investors, TPG Capital and HBM Healthcare Investments. https://www.sailife.com/

Photo: link Logo: link

View original content:enlace

Yorum yapabilmek için üye girişi yapmanız gerekmektedir.

Üye değilseniz hemen üye olun veya giriş yapın.

NEXT NEWS